Group 1 - The core issue revolves around allegations of financial fraud against Huaxi Biological, initiated by a former employee who claims the company and its controlling shareholder engaged in deceptive practices [1][2] - Huaxi Biological responded by stating that the allegations were investigated during the IPO review process in 2019 and were found to be unfounded, with relevant disclosures made in the prospectus [2][3] - The former employee, referred to as Li, claims that the accusations against him regarding embezzlement are false and that he reported the company for financial misconduct [1][3] Group 2 - The allegations include claims that Huaxi Xinyu Investment, the controlling shareholder, concealed the fact of holding 30 million shares of Jinzhou Bank and committed fraud during bond issuance [1][3] - As of the first quarter of 2025, Huaxi Xinyu holds 283.5 million shares of Huaxi Biological, representing a 58.86% ownership stake [1] - In 2020, the Beijing Securities Regulatory Bureau issued a warning letter to Huaxi Xinyu for inaccuracies in financial data disclosed during the issuance of exchangeable bonds [2] Group 3 - The former employee asserts that the warning letter from the regulatory body was a result of his whistleblowing, providing partial evidence to the regulatory authorities [3] - The allegations also include claims of significant omissions in the documentation submitted during Jinzhou Bank's IPO in December 2015, where Huaxi Xinyu allegedly made false commitments regarding shareholding [3] - Huaxi Biological's prospectus states that Huaxi Xinyu's shareholding was below 5%, thus not classified as a major shareholder and not obligated to disclose information during the overseas listing process [3][4]